Delivery Order SPE2DB22D3004-SPE2DB25FRU60
- Not listed
- The Defense Logistics Agency awarded a $17,412.86 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Mesalamine 800 mg delayed-release medication, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,914.97. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The order is set to be completed by July 31, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120-count packaging) with a ceiling value of $1,860.58. The contract was competitively awarded without a set-aside designation and is classified as a firm fixed price delivery order with an ultimate completion date of June 26, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count packaging) under a firm fixed-price contract valued at $1,014.56. This non-set-aside delivery order represents a small-value pharmaceutical procurement with a completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on July 31, 2025, with a ceiling value of $1,422.22 and an ultimate completion date of August 1, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical procurement needs. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,076.10. This non-set-aside award is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for...
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,320.87. This is a firm fixed price delivery order with no set-aside designation, executed through competitive procurement. The order is scheduled for ultimate completion on July 22, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,789.51 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This firm fixed-price delivery order, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a $2,113.94 delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRU60Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,681.52 to AmerisourceBergen Drug Corp for the supply of Mesalamine 800 mg delayed-release tablets (180-count units). This firm fixed-price delivery order, issued on August 1, 2025, represents a non-set-aside competitive award with an ultimate completion date of August 4, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor supplying critical medical commodities to federal healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal procurement portfolio demonstrates significant capability in fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, positioning the company as a key vendor for Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.7k | 8/1/25 |